<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201201128677N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-01-19</date_registration>
      <primary_sponsor>Vice Chancellor for research, Guilan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison the effects of intrathecal fentanyl, pethidine or placebo added to lidocaine and epinephrine on the duration of postoperative analgesia in spinal anesthesia for elective cesarean delivery.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the effects of intrathecal fentanyl, pethidine or placebo added to lidocaine and epinephrine on the duration of postoperative analgesia in spinal anesthesia for elective cesarean delivery.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-11-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>195</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/9162</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Pregnancy, childbirth and the puerperium.</hc_freetext>
      <i_freetext>Intervention 1: Prescription of 25 microgram fentanyl and 75 mg lidocaine and 0.02mg epinephrine to intervention group. Intervention 2: Prescription 25 mg pethidine and 75 mg lidocaine and 0.02mg epinephrine to intervention group. Intervention 3: Prescription of 1.5 ml normal saline and 75 mg lidocaine and 0.02mg epinephrine to control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farnoush Farzi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Reproduction Health Research Center, Al-Zahra hospital, Namjo street</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 13 1322 5624</telephone>
        <email>farnoush_farzi@gums.ac.ir</email>
        <affiliation>Guilan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farnoush Farzi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Reproduction Health Research Center, Al-Zahra hospital, Namjo street</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 13 1322 5624</telephone>
        <email>farnoush_farzi@gums.ac.ir</email>
        <affiliation>Guilan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: being candidate for elective cesarean delivery; ASA class 1&amp;2 and signing informed consent.&#13;
Exclusion criteria: addiction; contraindications for spinal anesthesia; hypersensitivity to opioids and local anesthetics; gestational hypertension; chronic itching; multi parity; having two or more surgery together and the duration of operation longer than 1.5 hours.</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of anaesthesia during labour and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Prescription of 25 microgram fentanyl and 75 mg lidocaine and 0.02mg epinephrine to intervention group.</i_keyword>
      <i_keyword>Prescription 25 mg pethidine and 75 mg lidocaine and 0.02mg epinephrine to intervention group.</i_keyword>
      <i_keyword>Prescription of 1.5 ml normal saline and 75 mg lidocaine and 0.02mg epinephrine to control group</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determination of effect of added fentanyl or pethidine in compare with normal saline to lidocaine and epinephrine on the duration of postoperative analgesia in spinal anesthesia for elective cesarean delivery. Timepoint: After delivery, then every 1 hour in the first 6 hours and every 2 hours in the latter 18 hours. Method of measurement: By using VAS score with a scaled liner with scaling from 0 to 10.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Determination of frequency of blood pressure decline after delivery in three groups. Timepoint: During delivery, then every 1 hour in the first 6 hours and every 2 hours in the latter 18 hours. Method of measurement: Noninvasive blood pressure measuring.</sec_outcome>
      <sec_outcome>Determination of frequency of nausea in three groups. Timepoint: During delivery, then every 1 hour in the first 6 hours and every 2 hours in the latter 18 hours. Method of measurement: Questioning from patient(having or not).</sec_outcome>
      <sec_outcome>Determination of frequency of vomiting in three groups. Timepoint: During delivery, then every 1 hour in the first 6 hours and every 2 hours in the latter 18 hours. Method of measurement: Observation the patient.</sec_outcome>
      <sec_outcome>Determination of infant’s APGAR in three groups. Timepoint: After infant’s birth and every 5 minute till the 20th minute. Method of measurement: APGAR score.</sec_outcome>
      <sec_outcome>Determination of frequency of itching in three groups. Timepoint: During delivery, then every 1 hour in the first 6 hours and every 2 hours in the latter 18 hours. Method of measurement: Questioning from patient(having or not).</sec_outcome>
      <sec_outcome>Comparison of frequency of sedation in three groups. Timepoint: During delivery, then every 1 hour in the first 6 hours and every 2 hours in the latter 18 hours. Method of measurement: Observation the patient.</sec_outcome>
      <sec_outcome>Determination of frequency of respiratory depression in three groups. Timepoint: During delivery, then every 1 hour in the first 6 hours and every 2 hours in the latter 18 hours. Method of measurement: Respiratory rate &lt;8 and o2 saturation with pulse oxymeter.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for research, Guilan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-10-31</approval_date>
        <contact_name>Ethic committee Guilan University of Medical Sciences</contact_name>
        <contact_address>Melat st, Namjoo Ave Rasht  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
